Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts

Adagene (NASDAQ: ADAG) announced the clinical development of ADG138, a dual-masked HER2-CD3 T-cell engager using SAFEbody technology. The company expects to begin dosing patients this quarter. Adagene also discussed potential autoimmune applications, partnerships with Third Arc Bio, Sanofi, and Exelixis, and upcoming catalysts, including Phase II data for muzastotug in 2027.

Original reporting
Published Oct 16, 2026, 6:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 6:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts — source image
Decision brief

The 30-second read

$ADAGNeutralMed
01

Why it matters

The IND clearance and upcoming Phase I trial for ADG138 provide a fresh catalyst that could move the stock.

02

Market read

First‑in‑human trial start is a primary corporate event that may drive short‑term volatility and longer‑term valuation.

03

What to watch

Funding constraints or competition from larger biotech firms could limit commercial upside.

Relevance 7/10Novelty 7/10Timing: this quarter

Background

Adagene (NASDAQ:ADAG) is a biotech focused on antibody‑based cancer immunotherapies, recently highlighting its SAFEbody pipeline.

Company-level read

Ticker impact

$ADAGNeutralHigh confidence
Context

Adagene received clearance from China's CDE to start a first‑in‑human IND study for its ADG138 T‑cell engager, with dosing expected this quarter.

Expected impact

potential upside as investors price in successful early‑phase data

Evidence & confidence

First‑in‑human study is a primary disclosure; positive data could lift the stock, while failure could pressure it.

Market effects

Advances in masked T‑cell engagers may influence biotech peers developing similar immunotherapies.

China's regulatory clearance highlights growing biotech activity in the region.

Successful data could attract broader investor interest in next‑gen immuno‑oncology platforms.

Counterpoint

If early‑phase data are disappointing, the stock could face a sharp decline despite the milestone.

Key entities

  • Adagene Inc.

    Biotech developing masked antibody therapeutics.

  • Third Arc Bio

    Collaboration partner for Adagene's platform.

  • Sanofi

    Strategic investor and co‑developer of immunotherapies.

Related articles

$ADAGLowAI 8/10

Adagene completes enrollment in phase 2 trial of muzastotug

Adagene Inc. (ADAG) completed enrollment in a Phase 2 trial of muzastotug, an anti-CTLA-4 antibody therapy, combined with Merck’s KEYTRUDA for late-line colorectal cancer. The trial enrolled 60 patients, with results expected in early 2027. The FDA confirmed Phase 3 trial design elements, and Sanofi invested in the trial. Muzastotug has FDA Fast Track designation.